NCT00104845View on ClinicalTrials.gov

Vaccine Therapy in Treating Patients With Stage IIB, Stage IIC, Stage III, or Stage IV Melanoma

PHASE1CompletedINTERVENTIONAL
Enrollment

19

Participants

Timeline

Start Date

September 30, 2004

Primary Completion Date

September 30, 2011

Study Completion Date

September 30, 2011

Conditions
Melanoma (Skin)
Interventions
BIOLOGICAL

human gp100 plasmid DNA vaccine

BIOLOGICAL

mouse gp100 plasmid DNA vaccine

Trial Locations (1)

10021

Memorial Sloan-Kettering Cancer Center, New York

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

Memorial Sloan Kettering Cancer Center

OTHER

NCT00104845 - Vaccine Therapy in Treating Patients With Stage IIB, Stage IIC, Stage III, or Stage IV Melanoma | Biotech Hunter | Biotech Hunter